Kyowa Kirin Co., Ltd.
Financial Summary Supplementary Materials ― Supplement to the Q3 Financial Summary for the Fiscal Year Ending December 2026 ―
Discloses consolidated results for Q3 of the fiscal year ending December 2026. Provides supplementary materials including trends in revenue, operating profit and core EPS, regional sales breakdown, major product developments, and the status of the development pipeline.
Key Figures
- Revenue: 4,968 hundred million yen (cumulative)
- Core Operating Income: 1,098 hundred million yen (cumulative)
- Core EPS: Unknown
AI要約
Overview of Performance
These materials were prepared as a supplement to the Q3 financial summary for the fiscal year ending December 2026 and cover trends in consolidated results, revenue by regional operating company, status of major products, and the latest information on the development pipeline. Cumulative revenue is approximately 4,968 hundred million yen, core operating income is approximately 1,098 hundred million yen, and core EPS is presented as a metric calculated using the weighted average number of shares outstanding during the period. The materials also include the regional sales composition, contributions of key products, and trends in technology income and royalties.
Outlook and Development Trends
The development pipeline includes multiple candidates progressing through Phase I to III. Collaborative products, including those co-developed with Kura Oncology, are also included, positioning overseas expansion and new indication expansion as future growth drivers. Exchange rate information is attached, and attention should be paid to profitability trends in global markets.
Kyowa Kirin Co., Ltd.
Company overview · Stock price · Financial data · All IR
